Allogene therapeutics announces participation in the td cowen 5th annual oncology innovation summit

South san francisco, calif., may 23, 2024 (globe newswire) -- allogene therapeutics, inc. (nasdaq: allo), a clinical-stage biotechnology company pioneering the development of allogeneic car t (allocar t™) products for cancer and autoimmune disease, today announced it will participate in the td cowen 5th annual oncology innovation summit.
COWN Ratings Summary
COWN Quant Ranking